New data, designation bolster BeiGene's planned submissions

BeiGene Ltd. (NASDAQ:BGNE) reported response rate data from a pivotal, Chinese Phase II trial of PD-1 inhibitor tislelizumab (BGB-A317) to treat classical Hodgkin's lymphoma (cHL), for which the company is planning a regulatory submission this year. The company also said zanubrutinib (BGB-3111) received Fast Track designation from FDA to treat Waldenström

Read the full 513 word article

User Sign In